


### **Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (PREVIOUSLY PRESENTED) A compound of formula



wherein  $W^6$  and  $X^6$  are  $-CR^1R^2$ ;  $Y^5$  is selected from the group consisting of  $-(CH_2)_a$ -CONH-Bm,  $-CH_2-(CH_2OCH_2)_b-CH_2$ -CONH-Bm,  $-(CH_2)_a$ -NHCO-Bm,  $-CH_2-(CH_2OCH_2)_b$ -CH<sub>2</sub>-NHCO-Bm,  $-(CH_2)_a$ -N(R<sup>3</sup>)-(CH<sub>2</sub>)<sub>b</sub>-CONH-Bm,  $(CH_2)_a$ -N(R<sup>3</sup>)-(CH<sub>2</sub>)<sub>c</sub>-NHCO-Bm,  $-(CH_2)_a$ -N(R<sup>3</sup>)-CH<sub>2</sub>-(CH<sub>2</sub>OCH<sub>2</sub>)<sub>b</sub>-CH<sub>2</sub>-CONH-Bm,  $-(CH_2)_a$ -N(R<sup>3</sup>)-CH<sub>2</sub>-(CH<sub>2</sub>OCH<sub>2</sub>)<sub>b</sub>-CH<sub>2</sub>-NHCO-Bm,  $-CH_2-(CH_2OCH_2)_b-CH_2$ -N(R<sup>3</sup>)-(CH<sub>2</sub>)<sub>a</sub>-CONH-Bm,  $-CH_2-(CH_2OCH_2)_b$ -CH<sub>2</sub>-N(R<sup>3</sup>)-(CH<sub>2</sub>)<sub>a</sub>-NHCO-Bm,  $-CH_2-(CH_2OCH_2)_b$ -CH<sub>2</sub>-N(R<sup>3</sup>)-CH<sub>2</sub>-(CH<sub>2</sub>OCH<sub>2</sub>)<sub>d</sub>-CONH-Bm,  $-CH_2-(CH_2OCH_2)_b$ -CH<sub>2</sub>-N(R<sup>3</sup>)-CH<sub>2</sub>-(CH<sub>2</sub>OCH<sub>2</sub>)<sub>d</sub>-NHCO-Bm,  $-(CH_2)_a$ -NR<sup>3</sup>R<sup>4</sup>, and  $-CH_2(CH_2OCH_2)_b$ -CH<sub>2</sub>NR<sup>3</sup>R<sup>4</sup>;  $Z^5$  is selected from the group consisting of  $-(CH_2)_a$ -CONH-Dm,  $-CH_2-(CH_2OCH_2)_b$ -CH<sub>2</sub>-CONH-Dm,  $-(CH_2)_a$ -NHCO-Dm,  $-CH_2-(CH_2OCH_2)_b$ -CONH-Dm,  $-CH_2-(CH_2OCH_2)_b$ -NHCO-Dm,  $-CH_2-(CH_2OCH_2)_b$ -NR<sup>3</sup>R<sup>4</sup>, and  $-CH_2(CH_2OCH_2)_b$ -CH<sub>2</sub>NR<sup>3</sup>R<sup>4</sup>.

$\text{CH}_2\text{-NHCO-Dm}$ ,  $-(\text{CH}_2)_a\text{-N}(\text{R}^3)\text{-}(\text{CH}_2)_b\text{-CONH-Dm}$ ,  $(\text{CH}_2)_a\text{-N}(\text{R}^3)\text{-}(\text{CH}_2)_c\text{-NHCO-Dm}$ ,  $-(\text{CH}_2)_a\text{-N}(\text{R}^3)\text{-CH}_2\text{-}(\text{CH}_2\text{OCH}_2)_b\text{-CH}_2\text{-CONH-Dm}$ ,  $-(\text{CH}_2)_a\text{-N}(\text{R}^3)\text{-CH}_2\text{-}(\text{CH}_2\text{OCH}_2)_b\text{-CH}_2\text{-NHCO-Dm}$ ,  $-\text{CH}_2\text{-}(\text{CH}_2\text{OCH}_2)_b\text{-CH}_2\text{-N}(\text{R}^3)\text{-}(\text{CH}_2)_c\text{-CONH-Dm}$ ,  $-\text{CH}_2\text{-}(\text{CH}_2\text{OCH}_2)_b\text{-CH}_2\text{-N}(\text{R}^3)\text{-CH}_2\text{-}(\text{CH}_2\text{OCH}_2)_d\text{-CONH-Dm}$ ,  $-\text{CH}_2\text{-}(\text{CH}_2\text{OCH}_2)_b\text{-CH}_2\text{-N}(\text{R}^3)\text{-CH}_2\text{-}(\text{CH}_2\text{OCH}_2)_d\text{-NHCO-Dm}$ ,  $-(\text{CH}_2)_a\text{-NR}^3\text{R}^4$ , and  $-\text{CH}_2\text{(CH}_2\text{OCH}_2)_b\text{-CH}_2\text{NR}^3\text{R}^4$ ;  $A_3$  is a single or a double bond;  $B_3$ ,  $C_3$ , and  $D_3$  are independently selected from the group consisting of  $-\text{O}-$ ,  $-\text{S}-$ ,  $-\text{Se}-$ ,  $-\text{P}-$ ,  $-\text{CR}^1\text{R}^2$ ,  $-\text{CR}^1$ , alkyl,  $\text{NR}^3$ , and  $-\text{C=O}$ ;  $A_3$ ,  $B_3$ ,  $C_3$ , and  $D_3$  may together form a 6- to 12-membered carbocyclic ring or a 6- to 12-membered heterocyclic ring optionally containing one or more oxygen, nitrogen, or sulfur atom;  $a_5$  vary from 0 to 5;  $R^1$  to  $R^4$ , and  $R^{68}$  to  $R^{66}$  are independently selected from the group consisting of hydrogen,  $\text{C}_1\text{-C}_{10}$  alkyl,  $\text{C}_6\text{-C}_{20}$  aryl,  $\text{C}_1\text{-C}_{10}$  alkoxy,  $\text{C}_1\text{-C}_{10}$  polyalkoxyalkyl,  $\text{C}_1\text{-C}_{20}$  polyhydroxyalkyl,  $\text{C}_6\text{-C}_{20}$  polyhydroxyaryl,  $\text{C}_1\text{-C}_{10}$  aminoalkyl, cyano, nitro, halogen, saccharide, peptide,  $-\text{CH}_2\text{(CH}_2\text{OCH}_2)_b\text{-CH}_2\text{-OH}$ ,  $-(\text{CH}_2)_a\text{-CONH-Bm}$ ,  $-\text{CH}_2\text{-}(\text{CH}_2\text{OCH}_2)_b\text{-CH}_2\text{-CONH-Bm}$ ,  $-(\text{CH}_2)_a\text{-NHCO-Bm}$ ,  $-\text{CH}_2\text{-}(\text{CH}_2\text{OCH}_2)_b\text{-CH}_2\text{-NHCO-Bm}$ , and  $-\text{CH}_2\text{-}(\text{CH}_2\text{OCH}_2)_b\text{-CO}_2\text{H}$ ; Bm and Dm are independently selected from the group consisting of bioactive peptide, protein, cell, antibody, antibody fragment, saccharide, glycopeptide, peptidomimetic, drug, drug mimic, hormone, metal chelating agent, radioactive or nonradioactive metal complex, and echogenic agent; a and c independently vary from 1 to 20; b and d independently vary from 1 to 100.


2. (CURRENTLY AMENDED) The compound of claim 1 wherein W<sup>5</sup> and X<sup>5</sup> are independently selected from the group consisting of -C(CH<sub>3</sub>)<sub>2</sub>, -C((CH<sub>2</sub>)<sub>a</sub>OH)CH<sub>3</sub>, -C((CH<sub>2</sub>)<sub>a</sub>OH)<sub>2</sub>, -C((CH<sub>2</sub>)<sub>a</sub>CO<sub>2</sub>H)CH<sub>3</sub>, -C((CH<sub>2</sub>)<sub>a</sub>CO<sub>2</sub>H)<sub>2</sub>, -C((CH<sub>2</sub>)<sub>a</sub>NH<sub>2</sub>)CH<sub>3</sub>, C((CH<sub>2</sub>)<sub>a</sub>NH<sub>2</sub>)<sub>2</sub>, C((CH<sub>2</sub>)<sub>a</sub>NR<sup>3</sup>R<sup>4</sup>)<sub>2</sub>; Y<sup>5</sup> is selected from the group consisting of -(CH<sub>2</sub>)<sub>a</sub>-CONH-Bm, -CH<sub>2</sub>-(CH<sub>2</sub>OCH<sub>2</sub>)<sub>b</sub>-CH<sub>2</sub>-CONH-Bm, -(CH<sub>2</sub>)<sub>a</sub>-NHCO-Bm, -CH<sub>2</sub>-(CH<sub>2</sub>OCH<sub>2</sub>)<sub>b</sub>-CH<sub>2</sub>-NHCO-Bm, -(CH<sub>2</sub>)<sub>a</sub>-NR<sup>3</sup>R<sup>4</sup>, and -CH<sub>2</sub>(CH<sub>2</sub>OCH<sub>2</sub>)<sub>b</sub>-CH<sub>2</sub>NR<sup>3</sup>R<sup>4</sup>; Z<sup>5</sup> is selected from the group consisting of -(CH<sub>2</sub>)<sub>a</sub>-CONH-Dm, -CH<sub>2</sub>-(CH<sub>2</sub>OCH<sub>2</sub>)<sub>b</sub>-CH<sub>2</sub>-CONH-Dm, -(CH<sub>2</sub>)<sub>a</sub>-NHCO-Dm, -CH<sub>2</sub>-(CH<sub>2</sub>OCH<sub>2</sub>)<sub>b</sub>-CH<sub>2</sub>-NHCO-Dm, -(CH<sub>2</sub>)<sub>a</sub>-NR<sup>3</sup>R<sup>4</sup>, and -CH<sub>2</sub>(CH<sub>2</sub>OCH<sub>2</sub>)<sub>b</sub>-CH<sub>2</sub>NR<sup>3</sup>R<sup>4</sup>; A<sub>3</sub> is a single or a double bond; B<sub>3</sub>, C<sub>3</sub>, and D<sub>3</sub> are independently selected from the group consisting of -O-, -S-, NR<sup>3</sup>, (CH<sub>2</sub>)<sub>a</sub>-CR<sup>1</sup>R<sup>2</sup>, and -CR<sup>1</sup>; A<sub>3</sub>, B<sub>3</sub>, C<sub>3</sub>, and D<sub>3</sub> may together form a 6- to 10-membered carbocyclic ring or a 6- to 10-membered heterocyclic ring optionally containing one or more oxygen, nitrogen, or sulfur atom; a<sub>5</sub> vary from 0 to 3; R<sup>1</sup> to R<sup>4</sup>, and R<sup>58</sup> to R<sup>66</sup> are independently selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>5</sub>-C<sub>12</sub> aryl, C<sub>1</sub>-C<sub>10</sub> alkoxy, C<sub>1</sub>-C<sub>10</sub> polyhydroxyalkyl, C<sub>5</sub>-C<sub>12</sub> polyhydroxyaryl, C<sub>1</sub>-C<sub>10</sub> aminoalkyl, mono- or oligosaccharide, peptide with 2 to 30 amino acid units, -CH<sub>2</sub>(CH<sub>2</sub>OCH<sub>2</sub>)<sub>b</sub>-CH<sub>2</sub>-OH, -(CH<sub>2</sub>)<sub>a</sub>-CONH-Bm, -CH<sub>2</sub>-(CH<sub>2</sub>OCH<sub>2</sub>)<sub>b</sub>-CH<sub>2</sub>-CONH-Bm, -(CH<sub>2</sub>)<sub>a</sub>-NHCO-Bm, -CH<sub>2</sub>-(CH<sub>2</sub>OCH<sub>2</sub>)<sub>b</sub>-CH<sub>2</sub>-NHCO-Bm, and -CH<sub>2</sub>-(CH<sub>2</sub>OCH<sub>2</sub>)<sub>b</sub>-CO<sub>2</sub>H; Bm and Dm are independently selected from the group consisting of bioactive peptide containing 2 to 30 amino acid units, antibody, mono- or oligosaccharide, glycopeptide, metal chelating agent, radioactive or nonradioactive metal complex,

and echogenic agent; a and c independently vary from 1 to 10; b and d independently vary from 1 to 30.

3. (CURRENTLY AMENDED) The compound of claim 2 wherein each of W<sup>5</sup> and X<sup>5</sup> is  $\text{C}((\text{CH}_2)\text{OH})_2$   $\text{C}(\text{CH}_3)_2$ ; Y<sup>5</sup> is  $-(\text{CH}_2)_2\text{-CONH-Bm}$ ; Z<sup>5</sup> is  $-(\text{CH}_2)_2\text{-CONH-Dm}$ ; A<sub>3</sub> is a single bond; A<sub>3</sub>, B<sub>3</sub>, C<sub>3</sub>, and D<sub>3</sub> together form a 6-membered carbocyclic ring; a<sub>5</sub> is 1; R<sup>58</sup> is galactose; each R<sup>59</sup> to R<sup>66</sup> is hydrogen; Bm is Octreotide; Dm is bombesin (7-14).

4. (PREVIOUSLY PRESENTED) A method for performing a diagnostic or therapeutic procedure comprising

administering to an individual an effective amount of the compound of formula



wherein  $W^5$  and  $X^5$  are  $-CR^1R^2$ ;  $Y^5$  is selected from the group consisting of  $-(CH_2)_a-$   $CONH-Bm$ ,  $-CH_2-(CH_2OCH_2)_b-CH_2-CONH-Bm$ ,  $-(CH_2)_a-NHCO-Bm$ ,  $-CH_2-(CH_2OCH_2)_b-$   $CH_2-NHCO-Bm$ ,  $-(CH_2)_a-N(R^3)-(CH_2)_b-CONH-Bm$ ,  $(CH_2)_a-N(R^3)-(CH_2)_c-NHCO-Bm$ ,  $-(CH_2)_a-N(R^3)-CH_2-(CH_2OCH_2)_b-CH_2-CONH-Bm$ ,  $-(CH_2)_a-N(R^3)-CH_2-(CH_2OCH_2)_b-CH_2-$   $NHCO-Bm$ ,  $-CH_2-(CH_2OCH_2)_b-CH_2-N(R^3)-(CH_2)_a-CONH-Bm$ ,  $-CH_2-(CH_2OCH_2)_b-CH_2-$   $N(R^3)-(CH_2)_a-NHCO-Bm$ ,  $-CH_2-(CH_2OCH_2)_b-CH_2-N(R^3)-CH_2-(CH_2OCH_2)_d-CONH-Bm$ ,  $-CH_2-(CH_2OCH_2)_b-CH_2-N(R^3)-CH_2-(CH_2OCH_2)_d-NHCO-Bm$ ,  $-(CH_2)_a-NR^3R^4$ , and  $-CH_2(CH_2OCH_2)_b-CH_2NR^3R^4$ ;  $Z^5$  is selected from the group consisting of  $-(CH_2)_a-$   $CONH-Dm$ ,  $-CH_2-(CH_2OCH_2)_b-CH_2-CONH-Dm$ ,  $-(CH_2)_a-NHCO-Dm$ ,  $-CH_2-(CH_2OCH_2)_b-$   $CH_2-NHCO-Dm$ ,  $-(CH_2)_a-N(R^3)-(CH_2)_b-CONH-Dm$ ,  $(CH_2)_a-N(R^3)-(CH_2)_c-NHCO-Dm$ ,  $-(CH_2)_a-N(R^3)-CH_2-(CH_2OCH_2)_b-CH_2-CONH-Dm$ ,  $-(CH_2)_a-N(R^3)-CH_2-(CH_2OCH_2)_b-CH_2-$   $NHCO-Dm$ ,  $-CH_2-(CH_2OCH_2)_b-CH_2-N(R^3)-(CH_2)_a-CONH-Dm$ ,  $-CH_2-(CH_2OCH_2)_b-CH_2-$   $N(R^3)-(CH_2)_a-NHCO-Dm$ ,  $-CH_2-(CH_2OCH_2)_b-CH_2-N(R^3)-CH_2-(CH_2OCH_2)_d-CONH-Dm$ ,  $-CH_2-(CH_2OCH_2)_b-CH_2-N(R^3)-CH_2-(CH_2OCH_2)_d-NHCO-Dm$ ,  $-(CH_2)_a-NR^3R^4$ , and  $-CH_2(CH_2OCH_2)_b-CH_2NR^3R^4$ ;  $A_3$  is a single or a double bond;  $B_3$ ,  $C_3$ , and  $D_3$  are independently selected from the group consisting of  $-O-$ ,  $-S-$ ,  $-Se-$ ,  $-P-$ ,  $-CR^1R^2$ ,  $-CR^1$ , alkyl,  $NR^3$ , and  $-C=O$ ;  $A_3$ ,  $B_3$ ,  $C_3$ , and  $D_3$  may together form a 6- to 12-membered carbocyclic ring or a 6- to 12-membered heterocyclic ring optionally containing one or more oxygen, nitrogen, or sulfur atom;  $a_5$  vary from 0 to 5;  $R^1$  to  $R^4$ , and  $R^{58}$  to  $R^{66}$  are independently selected from the group consisting of hydrogen,  $C_1-C_{10}$  alkyl,  $C_5-C_{20}$  aryl,  $C_1-C_{10}$  alkoxy,  $C_1-C_{10}$  polyalkoxyalkyl,  $C_1-C_{20}$  polyhydroxyalkyl,  $C_5-C_{20}$

polyhydroxyaryl, C<sub>1</sub>-C<sub>10</sub> aminoalkyl, cyano, nitro, halogen, saccharide, peptide, -CH<sub>2</sub>(CH<sub>2</sub>OCH<sub>2</sub>)<sub>b</sub>-CH<sub>2</sub>-OH, -(CH<sub>2</sub>)<sub>a</sub>-CONH-Bm, -CH<sub>2</sub>-(CH<sub>2</sub>OCH<sub>2</sub>)<sub>b</sub>-CH<sub>2</sub>-CONH-Bm, -(CH<sub>2</sub>)<sub>a</sub>-NHCO-Bm, -CH<sub>2</sub>-(CH<sub>2</sub>OCH<sub>2</sub>)<sub>b</sub>-CH<sub>2</sub>-NHCO-Bm, and -CH<sub>2</sub>-(CH<sub>2</sub>OCH<sub>2</sub>)<sub>b</sub>-CO<sub>2</sub>H; Bm and Dm are independently selected from the group consisting of bioactive peptide, protein, cell, antibody, antibody fragment, saccharide, glycopeptide, peptidomimetic, drug, drug mimic, hormone, metal chelating agent, radioactive or nonradioactive metal complex, and echogenic agent; a and c independently vary from 1 to 20; b and d independently vary from 1 to 100, and a pharmaceutically acceptable carrier or excipient to form a composition,

activating the compound using light, and  
performing the diagnostic or therapeutic procedure.

5. (CURRENTLY AMENDED) The method of claim 4 comprising administering to an individual an effective amount of the compound wherein W<sup>5</sup> and X<sup>5</sup> are independently selected from the group consisting of -C(CH<sub>3</sub>)<sub>2</sub>, -C((CH<sub>2</sub>)<sub>a</sub>OH)CH<sub>3</sub>, -C((CH<sub>2</sub>)<sub>a</sub>OH)<sub>2</sub>, -C((CH<sub>2</sub>)<sub>a</sub>CO<sub>2</sub>H)CH<sub>3</sub>, -C((CH<sub>2</sub>)<sub>a</sub>CO<sub>2</sub>H)<sub>2</sub>, -C((CH<sub>2</sub>)<sub>a</sub>NH<sub>2</sub>)CH<sub>3</sub>, C((CH<sub>2</sub>)<sub>a</sub>NH<sub>2</sub>)<sub>2</sub>, C((CH<sub>2</sub>)<sub>a</sub>NR<sup>3</sup>R<sup>4</sup>)<sub>2</sub>; Y<sup>6</sup> is selected from the group consisting of -(CH<sub>2</sub>)<sub>a</sub>-CONH-Bm, -CH<sub>2</sub>-(CH<sub>2</sub>OCH<sub>2</sub>)<sub>b</sub>-CH<sub>2</sub>-CONH-Bm, -(CH<sub>2</sub>)<sub>a</sub>-NHCO-Bm, -CH<sub>2</sub>-(CH<sub>2</sub>OCH<sub>2</sub>)<sub>b</sub>-CH<sub>2</sub>-NHCO-Bm, -(CH<sub>2</sub>)<sub>a</sub>-NR<sup>3</sup>R<sup>4</sup>, and -CH<sub>2</sub>-(CH<sub>2</sub>OCH<sub>2</sub>)<sub>b</sub>-CH<sub>2</sub>-NR<sup>3</sup>R<sup>4</sup>; Z<sup>5</sup> is selected from the group consisting of -(CH<sub>2</sub>)<sub>a</sub>-CONH-Dm, -CH<sub>2</sub>-(CH<sub>2</sub>OCH<sub>2</sub>)<sub>b</sub>-CH<sub>2</sub>-CONH-Dm, -(CH<sub>2</sub>)<sub>a</sub>-NHCO-Dm, -CH<sub>2</sub>-(CH<sub>2</sub>OCH<sub>2</sub>)<sub>b</sub>-CH<sub>2</sub>-NHCO-Dm, -(CH<sub>2</sub>)<sub>a</sub>-NR<sup>3</sup>R<sup>4</sup>, and

-CH<sub>2</sub>(CH<sub>2</sub>OCH<sub>2</sub>)<sub>b</sub>-CH<sub>2</sub>NR<sup>3</sup>R<sup>4</sup>; A<sub>3</sub> is a single or a double bond; B<sub>3</sub>, C<sub>3</sub>, and D<sub>3</sub> are independently selected from the group consisting of -O-, -S-, NR<sup>3</sup>, (CH<sub>2</sub>)<sub>a</sub>-CR<sup>1</sup>R<sup>2</sup>, and -CR<sup>1</sup>; A<sub>3</sub>, B<sub>3</sub>, C<sub>3</sub>, and D<sub>3</sub> may together form a 6- to 10-membered carbocyclic ring or a 6- to 10-membered heterocyclic ring optionally containing one or more oxygen, nitrogen, or sulfur atom; a<sub>5</sub> vary from 0 to 3; R<sup>1</sup> to R<sup>4</sup>, and R<sup>66</sup> to R<sup>68</sup> are independently selected from the group consisting of hydrogen, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>5</sub>-C<sub>12</sub> aryl, C<sub>1</sub>-C<sub>10</sub> alkoxy, C<sub>1</sub>-C<sub>10</sub> polyhydroxyalkyl, C<sub>5</sub>-C<sub>12</sub> polyhydroxyaryl, C<sub>1</sub>-C<sub>10</sub> aminoalkyl, mono- or oligosaccharide, peptide with 2 to 30 amino acid units, -CH<sub>2</sub>(CH<sub>2</sub>OCH<sub>2</sub>)<sub>b</sub>-CH<sub>2</sub>-OH, -(CH<sub>2</sub>)<sub>a</sub>-CONH-Bm, -CH<sub>2</sub>-(CH<sub>2</sub>OCH<sub>2</sub>)<sub>b</sub>-CH<sub>2</sub>-CONH-Bm, -(CH<sub>2</sub>)<sub>a</sub>-NHCO-Bm, -CH<sub>2</sub>-(CH<sub>2</sub>OCH<sub>2</sub>)<sub>b</sub>-CH<sub>2</sub>-NHCO-Bm, and -CH<sub>2</sub>-(CH<sub>2</sub>OCH<sub>2</sub>)<sub>b</sub>-CO<sub>2</sub>H; Bm and Dm are independently selected from the group consisting of bioactive peptide containing 2 to 30 amino acid units, antibody, mono- or oligosaccharide, glycopeptide, metal chelating agent, radioactive or nonradioactive metal complex, and echogenic agent; a and c independently vary from 1 to 10; b and d independently vary from 1 to 30.

6. (CURRENTLY AMENDED) The method of claim 5 comprising administering to an individual an effective amount of the compound wherein each W<sup>5</sup> and X<sup>5</sup> is ε(CH<sub>2</sub>OH)<sub>2</sub>-C(CH<sub>3</sub>)<sub>2</sub>; Y<sup>5</sup> is -(CH<sub>2</sub>)<sub>2</sub>-CONH-Bm; Z<sup>5</sup> is -(CH<sub>2</sub>)<sub>2</sub>-CONH-Dm; A<sub>3</sub> is a single bond; A<sub>3</sub>, B<sub>3</sub>, C<sub>3</sub>, and D<sub>3</sub> together form a 6-membered carbocyclic ring; a<sub>5</sub> is 1; R<sup>58</sup> is galactose; each R<sup>59</sup> to R<sup>68</sup> is hydrogen; Bm is Octreotide; Dm is bombesin (7-14).

7. (ORIGINAL) The method of claim 4 wherein said procedure uses light of wavelength in the region of 350-1300 nm.
8. (ORIGINAL) The method of claim 4 wherein the diagnostic procedure is optical tomography.
9. (ORIGINAL) The method of claim 4 wherein the diagnostic procedure is fluorescence endoscopy.
10. (ORIGINAL) The method of claim 4 further comprising monitoring a blood clearance profile of said compound by fluorescence, absorbance or light scattering wherein light of wavelength in the region of 350-1300 nm is used.
11. (ORIGINAL) The method of claim 4 wherein said procedure further comprises a step of imaging and therapy wherein said imaging and therapy is selected from the group consisting of absorption, light scattering, photoacoustic and sonofluorescence technique.
12. (ORIGINAL) The method of claim 4 wherein said procedure is for diagnosing atherosclerotic plaques and blood clots.
13. (ORIGINAL) The method of claim 4 wherein said procedure comprises administering localized therapy.


14. (ORIGINAL) The method of claim 4 wherein said therapeutic procedure comprises photodynamic therapy.

15. (ORIGINAL) The method of claim 4 wherein said therapeutic procedure comprises laser assisted guided surgery for the detection of micrometastases.

16. (PREVIOUSLY PRESENTED) The method of claim 4 further comprising adding a biocompatible organic solvent to the compound at a concentration of one to fifty percent to the composition to prevent *in vivo* or *in vitro* fluorescence quenching.

17. (ORIGINAL) The method of claim 16 wherein said compound is dissolved in a medium comprising one to fifty percent dimethyl sulfoxide.

18. (PREVIOUSLY PRESENTED) A composition comprising a cyanine dye bioconjugate of formula



wherein  $W^5$  and  $X^5$  are  $-CR^1R^2$ ;  $Y^5$  is selected from the group consisting of  $-(CH_2)_a-$ CONH-Bm,  $-CH_2-(CH_2OCH_2)_b-CH_2-CONH-Bm$ ,  $-(CH_2)_a-NHCO-Bm$ ,  $-CH_2-(CH_2OCH_2)_b-$  $CH_2-NHCO-Bm$ ,  $-(CH_2)_a-N(R^3)-(CH_2)_b-CONH-Bm$ ,  $(CH_2)_a-N(R^3)-(CH_2)_c-NHCO-Bm$ ,  $-(CH_2)_a-N(R^3)-CH_2-(CH_2OCH_2)_b-CH_2-CONH-Bm$ ,  $-(CH_2)_a-N(R^3)-CH_2-(CH_2OCH_2)_b-CH_2-$  $NHCO-Bm$ ,  $-CH_2-(CH_2OCH_2)_b-CH_2-N(R^3)-(CH_2)_a-CONH-Bm$ ,  $-CH_2-(CH_2OCH_2)_b-CH_2-$  $N(R^3)-(CH_2)_a-NHCO-Bm$ ,  $-CH_2-(CH_2OCH_2)_b-CH_2-N(R^3)-CH_2-(CH_2OCH_2)_a-CONH-Bm$ ,  $-CH_2-(CH_2OCH_2)_b-CH_2-N(R^3)-CH_2-(CH_2OCH_2)_a-NHCO-Bm$ ,  $-(CH_2)_a-NR^3R^4$ , and  $-CH_2(CH_2OCH_2)_b-CH_2NR^3R^4$ ;  $Z^5$  is selected from the group consisting of  $-(CH_2)_a-$ CONH-Dm,  $-CH_2-(CH_2OCH_2)_b-CH_2-CONH-Dm$ ,  $-(CH_2)_a-NHCO-Dm$ ,  $-CH_2-(CH_2OCH_2)_b-$  $CH_2-NHCO-Dm$ ,  $-(CH_2)_a-N(R^3)-(CH_2)_b-CONH-Dm$ ,  $(CH_2)_a-N(R^3)-(CH_2)_c-NHCO-Dm$ ,  $-(CH_2)_a-N(R^3)-CH_2-(CH_2OCH_2)_b-CH_2-CONH-Dm$ ,  $-(CH_2)_a-N(R^3)-CH_2-(CH_2OCH_2)_b-CH_2-$  $NHCO-Dm$ ,  $-CH_2-(CH_2OCH_2)_b-CH_2-N(R^3)-(CH_2)_a-CONH-Dm$ ,  $-CH_2-(CH_2OCH_2)_b-CH_2-$  $N(R^3)-(CH_2)_a-NHCO-Dm$ ,  $-CH_2-(CH_2OCH_2)_b-CH_2-N(R^3)-CH_2-(CH_2OCH_2)_a-CONH-Dm$ ,  $-CH_2-(CH_2OCH_2)_b-CH_2-N(R^3)-CH_2-(CH_2OCH_2)_a-NHCO-Dm$ ,  $-(CH_2)_a-NR^3R^4$ , and  $-CH_2(CH_2OCH_2)_b-CH_2NR^3R^4$ ;  $A_3$  is a single or a double bond;  $B_3$ ,  $C_3$ , and  $D_3$  are independently selected from the group consisting of  $-O-$ ,  $-S-$ ,  $-Se-$ ,  $-P-$ ,  $-CR^1R^2$ ,  $-CR^1$ , alkyl,  $NR^3$ , and  $-C=O$ ;  $A_3$ ,  $B_3$ ,  $C_3$ , and  $D_3$  may together form a 6- to 12-membered carbocyclic ring or a 6- to 12-membered heterocyclic ring optionally containing one or more oxygen, nitrogen, or sulfur atom;  $a_5$  vary from 0 to 5;  $R^1$  to  $R^4$ , and  $R^{58}$  to  $R^{66}$  are independently selected from the group consisting of hydrogen,  $C_1-C_{10}$  alkyl,

$C_5$ - $C_{20}$  aryl,  $C_1$ - $C_{10}$  alkoxy,  $C_1$ - $C_{10}$  polyalkoxyalkyl,  $C_1$ - $C_{20}$  polyhydroxyalkyl,  $C_5$ - $C_{20}$  polyhydroxyaryl,  $C_1$ - $C_{10}$  aminoalkyl, cyano, nitro, halogen, saccharide, peptide,  $-CH_2(CH_2OCH_2)_b-CH_2-OH$ ,  $-(CH_2)_a-CONH-Bm$ ,  $-CH_2-(CH_2OCH_2)_b-CH_2-CONH-Bm$ ,  $-(CH_2)_a-NHCO-Bm$ ,  $-CH_2-(CH_2OCH_2)_b-CH_2-NHCO-Bm$ , and  $-CH_2-(CH_2OCH_2)_b-CO_2H$ ; Bm and Dm are independently selected from the group consisting of bioactive peptide, protein, cell, antibody, antibody fragment, saccharide, glycopeptide, peptidomimetic, drug, drug mimic, hormone, metal chelating agent, radioactive or nonradioactive metal complex, and echogenic agent; a and c independently vary from 1 to 20; b and d independently vary from 1 to 100, and a pharmaceutically acceptable carrier or excipient.

19. (CURRENTLY AMENDED) The composition of claim 18 wherein  $W^5$  and  $X^5$  are independently selected from the group consisting of  $-C(CH_3)_2$ ,  $-C((CH_2)_aOH)CH_3$ ,  $-C((CH_2)_aOH)_2$ ,  $-C((CH_2)_aCO_2H)CH_3$ ,  $-C((CH_2)_aCO_2H)_2$ ,  $-C((CH_2)_aNH_2)CH_3$ ,  $C((CH_2)_aNH_2)_2$ ,  $C((CH_2)_aNR^3R^4)_2$ ;  $Y^6$  is selected from the group consisting of  $-(CH_2)_a-CONH-Bm$ ,  $-CH_2-(CH_2OCH_2)_b-CH_2-CONH-Bm$ ,  $-(CH_2)_a-NHCO-Bm$ ,  $-CH_2-(CH_2OCH_2)_b-CH_2-NHCO-Bm$ ,  $-(CH_2)_a-NR^3R^4$ , and  $-CH_2(CH_2OCH_2)_b-CH_2NR^3R^4$ ;  $Z^5$  is selected from the group consisting of  $-(CH_2)_a-CONH-Dm$ ,  $-CH_2-(CH_2OCH_2)_b-CH_2-CONH-Dm$ ,  $-(CH_2)_a-NHCO-Dm$ ,  $-CH_2-(CH_2OCH_2)_b-CH_2-NHCO-Dm$ ,  $-(CH_2)_a-NR^3R^4$ , and  $-CH_2(CH_2OCH_2)_b-CH_2NR^3R^4$ ;  $A_3$  is a single or a double bond;  $B_3$ ,  $C_3$ , and  $D_3$  are independently selected from the group consisting of  $-O-$ ,  $-S-$ ,  $NR^3$ ,  $(CH_2)_a-CR^1R^2$ ,

and  $-CR^1$ ;  $A_3$ ,  $B_3$ ,  $C_3$ , and  $D_3$  may together form a 6- to 10-membered carbocyclic ring or a 6- to 10-membered heterocyclic ring optionally containing one or more oxygen, nitrogen, or sulfur atom;  $a_5$  vary from 0 to 3;  $R^1$  to  $R^4$ , and  $R^{58}$  to  $R^{66}$  are independently selected from the group consisting of hydrogen,  $C_1$ - $C_{10}$  alkyl,  $C_5$ - $C_{12}$  aryl,  $C_1$ - $C_{10}$  alkoxy,  $C_1$ - $C_{10}$  polyhydroxyalkyl,  $C_5$ - $C_{12}$  polyhydroxyaryl,  $C_1$ - $C_{10}$  aminoalkyl, mono- or oligosaccharide, peptide with 2 to 30 amino acid units,  $-CH_2(CH_2OCH_2)_b-CH_2-OH$ ,  $-(CH_2)_a-CONH-Bm$ ,  $-CH_2-(CH_2OCH_2)_b-CH_2-CONH-Bm$ ,  $-(CH_2)_a-NHCO-Bm$ ,  $-CH_2-(CH_2OCH_2)_b-CH_2-NHCO-Bm$ ,  $-(CH_2)_a-OH$  and  $-CH_2-(CH_2OCH_2)_b-CO_2H$ ; Bm and Dm are independently selected from the group consisting of bioactive peptide containing 2 to 30 amino acid units, antibody, mono- or oligosaccharide, glycopeptide, metal chelating agent, radioactive or nonradioactive metal complex, and echogenic agent; a and c independently vary from 1 to 10; b and d independently vary from 1 to 30.

20. (CURRENTLY AMENDED) The composition of claim 19 wherein each of  $W^5$  and  $X^6$  is  $\text{G}((CH_2)_2OH)_2-C(CH_3)_2$ ;  $Y^5$  is  $-(CH_2)_2-CONH-Bm$ ;  $Z^5$  is  $-(CH_2)_2-CONH-Dm$ ;  $A_3$  is a single bond;  $A_3$ ,  $B_3$ ,  $C_3$ , and  $D_3$  together form a 6-membered carbocyclic ring;  $a_5$  is 1;  $R^{58}$  is galactose; each  $R^{59}$  to  $R^{66}$  is hydrogen; Bm is Octreotide; Dm is bombesin (7-14), and a pharmaceutically acceptable carrier or excipient.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**